RET and neoplasm: The results showed that the probability of achieving ORR in the previously treated patients was only 0.44 compared to the untreated patients, indicating that untreated RET fusion gene-positive NSCLC patients treated with RET-TKIs had better tumor response, ORR was better in RET fusion gene-positive NSCLC patients who had been untreated before (Fig. 2).